Sunshine Biopharma- Warrants (15/02/2027) Profit Margin

The latest profit margin for SBFMW is -17.45% as of September 2026. That compares with -16.06% in the prior-year period — down 8.7% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside Sunshine Biopharma- Warrants (15/02/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SBFMW's profit margin moved from -16.06% to -17.45% — a 8.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sunshine Biopharma- Warrants (15/02/2027)'s valuation or profitability profile.

Against Healthcare companies, SBFMW currently prints -17.45% for profit margin, while the sector average sits near 19.13%. That is roughly 191.2% below the sector mean. Large gaps often invite a closer look at Sunshine Biopharma- Warrants (15/02/2027)'s growth, margins, and balance sheet.

Profit Margin shows how effectively Sunshine Biopharma- Warrants (15/02/2027) converts resources into returns. At -17.45%, SBFMW may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -16.06% in the prior-year period — down 8.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SBFMW's profit margin (-17.45%), review year-over-year change from -16.06%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.